Clinical trials

Ongoing Protocols : click on the protocol for the inclusion-exclusioncriteria (update 12/10/2017)

NON-SMALL CELL LUNG CANCER

Locally advanced

PET Boost
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC.

PEARLS (MSD)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.

Advanced

LDK378-NIVOLUMAB (Novartis)
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. 

INC280 (Capmatinib) (Novartis)
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

ABEMACICLIB – PEMBROLIZUMAB (Lilly)
A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV
Non-Small Cell Lung Cancer.

LXH254, LTT462 (Novartis)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. Temporarily on hold

CPDR001C2101 (Novartis)
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients.

SMALL CELL LUNG CANCER

Hippocampus Avoidance PCI vs PCI
Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial.

STIMULI (ETOP)
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.

MESOTHELIOMA

NINTEDANIB (Boehringer Ingelheim)
Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma.


OTHERS

For further information regarding protocols or clinical trial unit description, please contact the datamanagers:

christel.oyen@uzleuven.be
liesbet.peeters@uzleuven.be
stefanie.lepers@uzleuven.be                                                                                                                      raf.blomme@uzleuven.be